Form D · Biotechnology

Scorpion Therapeutics, Inc.

Boston, MA · CIK 0001811858

Offering snapshot reported Jul 16, 2024 · SEC filing

Reported sold
$126M
Offering amount: $150M
Investors reported
38
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jul 1, 2024
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jul 16, 2024Initial$125,694,186No comparison38SEC filing
Dec 7, 2020Initial$146,999,977No comparison22SEC filing
May 19, 2020Initial$24,681,250No comparison11SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
Yes
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-518868

Source: Form D, filed Jul 16, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Jeffrey Albers Director
Peter Joseph Campisi, Jr. Executive
Mark Chao Executive
Shelley Chu Director
Andrew Fedder Executive
Keith Flaherty Director
Jean Francois Formela Director
Adam Friedman Director, Executive
Gary Glick Director, Executive
Arjun Goyal Director
Erica Jackson Executive
Oleg Nodelman Director
Brian Piper Executive
Saurabh Saha Director
Otello Stampacchia Director
Darrin Stuart Executive
Amanda Valentino Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
1 Winthrop Square Suite 400
Boston, MA, 02110